Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17036641 | 0.89 | SLC6A4 (0.32) | HRH3HSD11B1SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL25123272 | 0.88 | SIGMAR1 (0.40) | HRH3HSD11B1SMN1; SMN2EPHX1SIGMAR1 | |
| SCHEMBL24764898 | 0.86 | GNAO1 (0.40) | SLC6A4SLC6A3EPHX1 | |
| SCHEMBL22848538 | 0.84 | CHRM4 (0.38) | HRH3SLC6A4SLC6A3CHRM4SIGMAR1 | |
| SCHEMBL17250047 | 0.81 | NCF1 (0.43) | HRH3SIGMAR1 | |
| SCHEMBL23696790 | 0.81 | — | — | |
| SCHEMBL23560045 | 0.81 | EPHX1 (0.41) | HRH3HSD11B1SMN1; SMN2EPHX1SIGMAR1 | |
| SCHEMBL8396257 | 0.80 | — | — | |
| SCHEMBL17702046 | 0.79 | HRH3 (0.42) | HRH3SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL23806161 | 0.79 | SIGMAR1 (0.35) | HRH3SIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021011634-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2020251969-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251972-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | HRH3 3874/4885HSD11B1 975/4885SLC6A4 4490/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HRH3 3631/4885HSD11B1 2834/4885SLC6A4 4814/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HRH3 3631/4885HSD11B1 2834/4885SLC6A4 4814/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HRH3 3631/4885HSD11B1 2834/4885SLC6A4 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.